Rapport Therapeutics Inc. (RAPP)
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RAPP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.37B
- EPS (TTM)
- -$3.17
- Dividend yield
- None
- 52-week range
- 22.06 – 52.93
- Day range
- 23.00 – 23.83
- Volume / Avg
- 437.72K / 790.62K
- Beta
- —
- Shares outstanding
- 59.28M
52-week range
RAPP stock today
On Nov 20, RAPP ended the session at $23.16, shedding $0.43 (1.82%), versus the S&P 500's 3.70% decline. Shares are 56.2% below their 52-week high of $52.93, set on Aug 27, 2026 and 5.0% above the 52-week low of $22.06, near the bottom of the past year's range. RAPP is down 23.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.0%.
Rapport Therapeutics has posted a net loss over the last twelve months (EPS of -$3.17), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Rapport Therapeutics
Company profileRapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Abraham N. Ceesay M.B.A.
- Headquarters
- Boston, MA
- Employees
- 84
- IPO year
- 2024
- Website
- rapportrx.com
Financial highlights
Full financialsRapport Therapeutics reported a net loss of $111.5 million, compared with a loss of $78.3 million a year earlier. Diluted earnings per share came in at -$2.86.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-111.48M | $-78.31M | $-34.79M |
| EPS (diluted) | $-2.86 | $-3.78 | $-23.10 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$64.21+177.25%
- Strong buy 1
- Buy 15
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.84 vs $-1.21
- Surprise
- +30.58%
RAPP news
All RAPP news- Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business UpdateGlobeNewswire
- Rapport Therapeutics Prices $380 Million Stock And Convertible Notes Offerings; Stock DownNasdaqRAPP, DDS
- Why is Rapport Therapeutics stock sliding today?Investing.com
- Rapport Therapeutics stock tumbles on $350M capital raiseInvesting.com
- Rapport Therapeutics slides after pricing securities offeringsSeeking Alpha
- Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private PlacementGlobeNewswire
- Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private PlacementGlobeNewswire
- Rapport Therapeutics Consensus Price Target Increased by 10.79% to $69.65NasdaqRAPP, BF.A
Rapport Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs RAPP |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs RAPP |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs RAPP |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs RAPP |
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs RAPP |
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs RAPP |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs RAPP |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs RAPP |
Indexes, lists and sector
Rapport Therapeutics stock FAQ
What is Rapport Therapeutics's stock price today?
RAPP last traded at $23.16 as of Nov 20, 4:00 PM EST, down 1.82% on the day. Prices are delayed at least 15 minutes.
Who is Rapport Therapeutics's CEO?
Mr. Abraham N. Ceesay M.B.A. is the chief executive officer of Rapport Therapeutics Inc., which has about 84 employees.
What is the RAPP 52-week high?
The 52-week high for RAPP is $52.93 and the 52-week low is $22.06. The stock is currently 56.2% below its high.